Profund Advisors LLC Increases Stock Position in Immunovant, Inc. $IMVT

Profund Advisors LLC raised its stake in shares of Immunovant, Inc. (NASDAQ:IMVT) by 120.4% in the 4th quarter, HoldingsChannel reports. The firm owned 49,076 shares of the company’s stock after purchasing an additional 26,810 shares during the period. Profund Advisors LLC’s holdings in Immunovant were worth $1,248,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of IMVT. ProShare Advisors LLC raised its position in shares of Immunovant by 14.9% during the 4th quarter. ProShare Advisors LLC now owns 20,553 shares of the company’s stock valued at $522,000 after buying an additional 2,660 shares in the last quarter. DNB Asset Management AS lifted its holdings in shares of Immunovant by 45.9% during the 4th quarter. DNB Asset Management AS now owns 18,109 shares of the company’s stock worth $460,000 after acquiring an additional 5,701 shares during the last quarter. Jennison Associates LLC purchased a new position in Immunovant in the fourth quarter worth $17,806,000. State of New Jersey Common Pension Fund D purchased a new position in Immunovant in the fourth quarter worth $605,000. Finally, UBS Group AG increased its stake in Immunovant by 0.9% in the fourth quarter. UBS Group AG now owns 732,386 shares of the company’s stock valued at $18,617,000 after acquiring an additional 6,213 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Stock Up 35.3%

Shares of NASDAQ:IMVT opened at $35.56 on Thursday. The stock has a market cap of $7.24 billion, a PE ratio of -13.22 and a beta of 0.70. The company’s fifty day moving average is $26.48 and its 200 day moving average is $25.78. Immunovant, Inc. has a 52 week low of $13.79 and a 52 week high of $36.29.

Immunovant (NASDAQ:IMVT) last posted its quarterly earnings results on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same quarter last year, the firm posted ($0.64) EPS. Sell-side analysts anticipate that Immunovant, Inc. will post -2.67 EPS for the current year.

Insider Buying and Selling

In related news, Director Atul Pande sold 6,000 shares of the stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $32.00, for a total transaction of $192,000.00. Following the completion of the sale, the director directly owned 116,731 shares in the company, valued at $3,735,392. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Graham Susman sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $27.17, for a total value of $67,979.34. Following the transaction, the director owned 36,394 shares in the company, valued at approximately $988,824.98. The trade was a 6.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 78,141 shares of company stock worth $2,115,713 in the last 90 days. 1.80% of the stock is currently owned by company insiders.

Key Stories Impacting Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant reported promising Week 16 data from its difficult-to-treat rheumatoid arthritis study, with strong response rates that investors are viewing as evidence the lead program could have meaningful clinical potential. QuiverQuant article
• Positive Sentiment: The company said its cutaneous lupus proof-of-concept study is fully enrolled, with topline results expected in the second half of 2026, keeping multiple catalysts ahead for IMVT-1402. GlobeNewswire article
• Neutral Sentiment: Immunovant reported quarterly results showing a wider-than-expected loss, with EPS of -$0.73 versus the -$0.60 consensus, but the earnings miss appears to have taken a back seat to the clinical update. Earnings report
• Neutral Sentiment: Management also highlighted a strong cash position of about $902 million at March 31, 2026, suggesting enough runway to support development plans through a potential commercial launch. GlobeNewswire article
• Negative Sentiment: Despite the stock’s rally, the company still faces execution risk because IMVT-1402 remains in clinical development and future results will need to confirm today’s optimistic early readout.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on IMVT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Wednesday, April 8th. Sanford C. Bernstein began coverage on Immunovant in a research report on Friday, March 20th. They set a “market perform” rating and a $28.00 price objective on the stock. The Goldman Sachs Group boosted their target price on Immunovant from $29.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Immunovant in a research note on Tuesday, February 10th. Finally, Guggenheim increased their price target on shares of Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $32.44.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.